Role of erythropoietin in cancer-related anemia: A double-edged sword?

Journal of International Medical Research

Volumn 36, Issue 1, 2008, Pages 1-8

  Guan, Xiaoxiang ^a   Chen, Longbong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Anaemia; Cancer; Cancer related anaemia; Chemotherapy; Erythropotetin; Radiotherapy; Tumours

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM COMPLEX; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ANEMIA; BLOOD TRANSFUSION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHROPOIESIS; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; META ANALYSIS; MONOTHERAPY; MORBIDITY; OVERALL SURVIVAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 39149087060     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600101     Document Type: Review

References (44)

1. Coiffier B: The impact and management of anaemia in haematological malignancies. Med Oncol 2000; 17(suppl 1): S2-S10.
2. Shasha D: The negative impact of anemia on radiotherapy and chemoradiation outcomes. Semin Hematol 2001; 38(3 suppl 7): 8-15.
3. Caro JJ, Salas M, Ward A, et al: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-2221.
4. Spivak JL: The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 2005; 5: 543-555.
5. Mercadante S: Pharmacotherapy of anaemia in cancer patients. Expert Opin Pharmacother 2001; 2: 1949-1961.
6. Desai J, Demetri GD: Recombinant human erythropoietin in cancer-related anemia: an evidence-based review. Best Pract Res Clin Haematol 2005; 18: 389-406.
7. Henke M, Laszig R, Rübe C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260.
8. Littlewood, TJ: The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001; 28 (2 suppl 8): 49-53.
9. Seidenfeld J, Piper M, Flamm C, et al: Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93: 1204-1214.
10. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-1234.
11. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16: 3412-3425.
12. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-2882.
13. Desai J, Demetri GD: Recombinant human erythropoietin in cancer-related anemia: an evidence-based review. Best Pract Res Clin Haematol 2005; 18: 389-406.
14. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
15. Quirt I, Kovacs M, Couture F, et al: Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience. Oncologist 2006; 11: 73-82.
16. Aapro MS, Dale D, Blasi M, et al: Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy. Support Care Cancer 2006; 14: 1184-1194.
17. Koshikawa N, Takenaga K: Hypoxia-regulated expression of attenuated diphtheria toxin A fused with hypoxia-inducible factor-1alpha oxygen-dependent degradation domain preferentially induces apoptosis of hypoxic cells in solid tumor. Cancer Res 2005; 65: 11622-11630.
18. Dunst J: The use of epoetin alfa to increase and maintain hemoglobin levels during radiotherapy. Semin Oncol 2001; 28 (2 suppl 8): 42-48.
19. Prutchi-Sagiv S, Golishevsky N, Oster HS, et al: Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Br J Haematol 2006; 135: 660-672.
20. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-5972.
21. Bouscary D, Pene F, Claessens YE, et al: Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003; 101: 3436-3443.
22. Hardee ME, Arcasoy MO, Blackwell KL, et al: Erythropoietin biology in cancer. Clin Cancer Res 2006; 12: 332-339.
23. Selzer E, Wacheck V, Kodym R, et al: Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000; 10: 421-426.
24. Dagnon K, Pacary E, Commo F, et al: Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 2005; 11: 993-999.
25. Osterborg A, Aapro M, Cornes P, et al: Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007; 43: 510-519.
26. Kumar SM, Yu H, Fong D, et al: Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res 2006; 16: 275-283.
27. Lai SY, Grandis JR: Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol 2006; 24: 4675-4676.
28. Pajonk F, Weil A, Sommer A, et al: The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 2004; 23: 8987-8991.
29. Acs G, Zhang PJ, McGrath CM, et al: Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003; 162: 1789-1806.
30. Lester RD, Jo M, Campana WM, et al: Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 2005; 280: 39273-39277.
31. Mohyeldin A, Lu H, Dalgard C, et al: Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005; 7: 536-543.
32. Lai SY, Childs LE, Xi S, et al: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005; 24: 4442-4449.
33. Henke M, Mattern D, Pepe M, et al: Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24: 4708-4713.
34. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: updated meta-ancilysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: 708-714.
35. Canaparo R, Casale F, Muntoni E, et al: Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 2000; 50: 146-153.
36. Bokemeyer C, Aapro MS, Courdi A, et al: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43: 258-270.
37. Spaeth D, Casadevall N, Daouphars M, et al: Summary version of the Standards, Options and Recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology - Update 2003. Bull Cancer 2004; 91: 179-188.
38. Katodritou E, Speletas M, Zervas K, et al: Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Lab Hematol 2006; 12: 47-54.
39. Steensma DP, Loprinzi CL: Erythropoietin use in cancer patients: a matter of life and death? J Clin Oncol 2005; 23: 5865-5868.
40. Macdougall IC, Eckardt KU: Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006; 368: 947-953.
41. Glaspy J, Vadhan-Raj S, Patel R, et al: Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006; 24: 2290-2297.
42. Vincent JL, Spapen HD, Creteur J, et al: Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Crit Care Med 2006; 34: 1661-1667.
43. Barton-Pai A, Chretien C, Lau AH: The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol 2002; 58: 38-46.
44. Tehranchi R: Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes. Med Oncol 2006; 23: 37-49.